Format

Send to

Choose Destination
Pharmacopsychiatry. 2016 Jul;49(4):155-61. doi: 10.1055/s-0042-101868. Epub 2016 Mar 7.

Use of Pregabalin - A Nationwide Pharmacoepidemiological Drug Utilization Study with Focus on Abuse Potential.

Author information

1
Department of Psychiatry, Aalborg University Hospital.
2
Clinical Pharmacology, Department of Public Health, University of Southern Denmark.
3
Danish Medicines Authority, Copenhagen, Denmark.

Abstract

INTRODUCTION:

Pregabalin is currently approved for the treatment of epilepsy, generalized anxiety disorder and neuropathic pain with a licensed dosage range of 150 mg to 600 mg/day. Growing concern about the abuse potential of pregabalin is partly based on reports of pregabalin being used in dosages that exceed the approved therapeutic range.

METHODS:

To identify predictors of pregabalin use above recommended dosage, we conducted a pharmacoepidemological drug utilization study using the Danish nationwide registers. We deployed 4 measures of abuse: high use (≥600 mg/day) or very high use (≥1 200 mg/day) over a 6- or 12-month period, respectively. Multiple logistic regression was used to identify patient and treatment characteristics that were associated with either abuse marker.

RESULTS:

Out of 42 520 pregabalin users 4 090 (9.6%) were treated with more than 600 mg/day for 6 months and 2 765 (6.5%) for more than 12 months. Male gender and prescription of antipsychotics and benzodiazepines were associated with increased risk of use of above the recommended dosage.

DISCUSSION:

Use of pregabalin above recommended dosages was rare but abuse may occur in susceptible patients.

PMID:
26951495
DOI:
10.1055/s-0042-101868
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York
Loading ...
Support Center